Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

Abstract Alzheimer’s disease (AD) drug development is burdened with the current requirement to conduct large, lengthy, and costly trials to overcome uncertainty in patient progression and effect size on treatment outcome measures. There is an urgent need for the discovery, development, and implement...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnerić, Stephen P., Batrla-Utermann, Richard, Beckett, Laurel, Bittner, Tobias, Blennow, Kaj, Carter, Leslie, Dean, Robert, Engelborghs, Sebastiaan, Genius, Just, Gordon, Mark Forrest, Hitchcock, Janice, Kaplow, June, Luthman, Johan, Meibach, Richard, Raunig, David, Romero, Klaus, Samtani, Mahesh N., Savage, Mary, Shaw, Leslie, Stephenson, Diane, Umek, Robert M., Vanderstichele, Hugo, Willis, Brian, Yule, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115607/
https://www.ncbi.nlm.nih.gov/pubmed/27662307
http://dx.doi.org/10.3233/JAD-160573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115607/
https://www.ncbi.nlm.nih.gov/pubmed/27662307
http://dx.doi.org/10.3233/JAD-160573

Ejemplares similares